stoxline Quote Chart Rank Option Currency Glossary
  
Virax Biolabs Group Limited (VRAX)
0.1882  -0.019 (-9.08%)    12-05 15:58
Open: 0.2101
High: 0.2195
Volume: 120,663
  
Pre. Close: 0.207
Low: 0.1863
Market Cap: 3(M)
Technical analysis
2023-12-05 4:23:36 PM
Short term     
Mid term     
Targets 6-month :  0.28 1-year :  0.32
Resists First :  0.24 Second :  0.28
Pivot price 0.23
Supports First :  0.18 Second :  0.15
MAs MA(5) :  0.21 MA(20) :  0.23
MA(100) :  0.32 MA(250) :  0.49
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  23.9 D(3) :  24.6
RSI RSI(14): 37.3
52-week High :  1.6 Low :  0.18
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ VRAX ] has closed above bottom band by 6.9%. Bollinger Bands are 36% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.22 - 0.22 0.22 - 0.22
Low: 0.18 - 0.18 0.18 - 0.19
Close: 0.2 - 0.2 0.2 - 0.2
Company Description

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Headline News

Tue, 05 Dec 2023
Reviewing Cardio Diagnostics (NASDAQ:CDIO) & Virax Biolabs Group (NASDAQ:VRAX) - Defense World

Tue, 12 Sep 2023
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts ... - PR Newswire

Fri, 01 Sep 2023
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum - PR Newswire

Thu, 03 Aug 2023
Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid - PR Newswire

Tue, 18 Jul 2023
Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities - PR Newswire

Wed, 14 Jun 2023
Virax Biolabs' CEO James Foster Issues Letter to Shareholders - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 18 (M)
Held by Insiders 1.095e+007 (%)
Held by Institutions 35.3 (%)
Shares Short 96 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -153 %
Return on Assets (ttm) 182.9 %
Return on Equity (ttm) -72.7 %
Qtrly Rev. Growth 8560 %
Gross Profit (p.s.) -0.01
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 50230
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android